|
1
|
Bourne RR, Stevens GA, White RA, et al:
Vision Loss Expert Group: Causes of vision loss worldwide,
1990–2010: A systematic analysis. Lancet Glob Health. 1:e339–e349.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong WL, Su X, Li X, Cheung CM, Klein R,
Cheng CY and Wong TY: Global prevalence of age-related macular
degeneration and disease burden projection for 2020 and 2040: A
systematic review and meta-analysis. Lancet Glob Health.
2:e106–e116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chakravarthy U, Harding SP, Rogers CA,
Downes SM, Lotery AJ, Culliford LA and Reeves BC: IVAN study
investigators: Alternative treatments to inhibit VEGF in
age-related choroidal neovascularisation: 2-year findings of the
IVAN randomised controlled trial. Lancet. 382:1258–1267. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrara N, Mass RD, Campa C and Kim R:
Targeting VEGF-A to treat cancer and age-related macular
degeneration. Annu Rev Med. 58:491–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duh EJ, Yang HS, Haller JA, et al:
Vitreous levels of pigment epithelium-derived factor and vascular
endothelial growth factor: Implications for ocular angiogenesis. Am
J Ophthalmol. 137:668–674. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta OP, Shienbaum G, Patel AH, Fecarotta
C, Kaiser RS and Regillo CD: A treat and extend regimen using
ranibizumab for neovascular age-related macular degeneration
clinical and economic impact. Ophthalmology. 117:2134–2140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jonas JB, Tao Y and Schlichtenbrede FC:
Intravitreal bevacizumab for exudative age-related macular
degeneration in clinical practice. J Ocul Pharmacol Ther.
27:467–470. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamashiro K, Tomita K, Tsujikawa A, Nakata
I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H and Yoshimura N:
Factors associated with the response of age-related macular
degeneration to intravitreal ranibizumab treatment. Am J
Ophthalmol. 154:125–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Avery RL, Pieramici DJ, Rabena MD,
Castellarin AA, Nasir MA and Giust MJ: Intravitreal bevacizumab
(Avastin) for neovascular age-related macular degeneration.
Ophthalmology. 113:363–372.e5. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mekjavic PJ, Kraut A, Urbancic M, Lenassi
E and Hawlina M: Efficacy of 12-month treatment of neovascular
age-related macular degeneration with intravitreal bevacizumab
based on individually determined injection strategies after three
consecutive monthly injections. Acta Ophthalmol (Copenh).
89:647–653. 2011. View Article : Google Scholar
|
|
11
|
Giani A, Cigada M, Choudhry N, Deiro AP,
Oldani M, Pellegrini sM, Invernizzi A, Duca P, Miller JW and
Staurenghi G: Reproducibility of retinal thickness measurements on
normal and pathologic eyes by different optical coherence
tomography instruments. Am J Ophthalmol. 150:815–824. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bentaleb-Machkour Z, Jouffroy E, Rabilloud
M, Grange JD and Kodjikian L: Comparison of central macular
thickness measured by three OCT models and study of interoperator
variability. Scientific World Journal. 2012:8427952012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krebs I, Lie S, Stolba U, Zeiler F, Felke
S and Binder S: Efficacy of intravitreal bevacizumab (Avastin)
therapy for early and advanced neovascular age-related macular
degeneration. Acta Ophthalmol (Copenh). 87:611–617. 2009.
View Article : Google Scholar
|
|
14
|
Martin DF, Maguire MG, Ying GS, Grunwald
JE, Fine SL and Jaffe GJ: CATT Research Group: Ranibizumab and
bevacizumab for neovascular age-related macular degeneration. N
Engl J Med. 364:1897–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bashshur ZF, Haddad ZA, Schakal A, Jaafar
RF, Saab M and Noureddin BN: Intravitreal bevacizumab for treatment
of neovascular age-related macular degeneration: A one-year
prospective study. Am J Ophthalmol. 145:249–256. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Francis PJ: The influence of genetics on
response to treatment with ranibizumab (Lucentis) for age-related
macular degeneration: the Lucentis Genotype Study (an American
Ophthalmological Society thesis). Trans Am Ophthalmol Soc.
109:115–156. 2011.PubMed/NCBI
|
|
17
|
Priya RR, Chew EY and Swaroop A: Genetic
studies of age-related macular degeneration: Lessons, challenges,
and opportunities for disease management. Ophthalmology.
119:2526–2536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cleary CA, Jungkim S, Ravikumar K,
Kelliher C, Acheson RW and Hickey-Dwyer M: Intravitreal bevacizumab
in the treatment of neovascular age-related macular degeneration,
6- and 9-month results. Eye (Lond). 22:82–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Penn JS, Madan A, Caldwell RB, Bartoli M,
Caldwell RW and Hartnett ME: Vascular endothelial growth factor in
eye disease. Prog Retin Eye Res. 27:331–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang C, Xu Y, Li X and Wang W: Vascular
endothelial growth factor A polymorphisms and age-related macular
degeneration: A systematic review and meta-analysis. Mol Vis.
19:1211–1221. 2013.PubMed/NCBI
|
|
21
|
Chopdar A, Chakravarthy U and Verma D: Age
related macular degeneration. BMJ. 326:485–488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lim LS, Mitchell P, Seddon JM, Holz FG and
Wong TY: Age-related macular degeneration. Lancet. 379:1728–1738.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coleman HR, Chan C-C, Ferris FL III and
Chew EY: Age-related macular degeneration. Lancet. 372:1835–1845.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levy J, Shneck M, Rosen S, Klemperer I,
Rand D, Weinstein O, Pitchkhadze A, Belfair N and Lifshitz T:
Intravitreal bevacizumab (avastin) for subfoveal neovascular
age-related macular degeneration. Int Ophthalmol. 29:349–357. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aisenbrey S, Ziemssen F, Volker M,
Gelisken F, Szurman P, Jaissle G, Grisanti S and Bartz-Schmidt KU:
Intravitreal bevacizumab (Avastin) for occult choroidal
neovascularization in age-related macular degeneration. Graefes
Arch Clin Exp Ophthalmol. 245:941–948. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
El Matri L, Bouraoui R, Chebil A, Kort F,
Bouladi M, Limaiem R and Landoulsi H: Bevacizumab injection in
patients with age-related macular degeneration associated with poor
initial visual acuity. J Ophthalmol. 2012:8613842012. View Article : Google Scholar : PubMed/NCBI
|
